Connecting you with your industry every day
Job losses across Australian pharma have stretched workforces - some to breaking point - with employees who have escaped redundancy, left to pick up the work of one, two, or three or more employees who have left
The Australian pharma job market is a journey for everyone, even Country Leaders, as this former boss has revealed
Twenty Aussie industry leaders gathered for the inaugural Medical Directors Breakfast on AI in Sydney, to unpack how AI is reshaping their teams
The Department has released guidance on how to use AI in PBAC submissions and established a rolling review of PBAC guidelines
Company heads into the PRIME Awards next week as a finalist for a staggering 10 campaigns across four categories. This is how they did it...
Companies lowered the amount they spent on HCPs each month in the first half of 2026, with just two pharmas getting into seven figures
In its first major deal just days after launching, Matt Zeller and Damian Clarke-Bruce's company has added an investigational one-time gene therapy to its pipeline
Consumer Healthcare Products Australia and its members have come together with Pharmacycle to take blister pack recycling to the next level
There's been a wave of movement across Australian pharma with promotions, new hires, departures and even a retirement as a new year looms
Scammers impersonating legitimate Big Pharma in-house recruiters are targeting Australian industry professionals with lucrative high-income roles as part of a money-making racket
After eight-plus years with the Aussie giant, this industry leader has taken a CEO role at a biotech with big ambitions to transform precision medicine
A theoretical side-effect of the gene therapy has appeared in practice, alarming patient networks around the world
Direct-to-patient programs are considered "mission critical" according to a third of pharma professionals who believe it will transform access
A national shortage of this treatment is expected to continue into 2027 after the pharma confirmed an order, expected this month, is now “unlikely”
New report on the Australian clinical trials workforce reveals the same people are either being reshuffled or lost, while others struggle to crack the market
A bombshell announcement from two industry high-flyers was kept completely under wraps despite multiple big-name organisations getting on board with the new pharma venture. And now, they've detailed a potentially market-disrupting business model for medicines access
An international private equity firm has reached an agreement to acquire this pharma, with plans to support its global growth ambitions
Aussie BMS staffers have raised double their original goal for Rare Cancers Australia through an 18,000 kilometre, 15-day cycling event in Japan
Five months after leaving Arrotex, the former Novartis Country President ANZ is launching his own Sydney-headquartered pharma company with another high-profile exec as Co-Founder
New research commissioned by Pfizer Australia exposes near-universal public support for expanding the PBS among Coalition, Labor, Greens and One Nation voters
The Swiss pharma is gathering experts to push its entrant into the booming next-generation sequencing market
Last week saw a string of medicines registered on the ARTG, including two heart drugs, a new contraceptive option, and Novo’s hyped obesity pill
He knows plenty about the role, having served as interim Managing Director for six months, now this leader has officially landed the top job, providing certainty for the pharma as it navigates a changing reimbursement landscape
More than four in 10 clinicians say conversations with reps are mostly about products but what they'd really like to discuss is this...
AstraZeneca leader joins board to promote trade between Europe and Australia bolstering collaboration, innovation and investment
Three drugs were removed and another added in a last-minute revision to the agenda for the PBAC's last three-day meeting for 2026
This company will now be a specialty pharma focused on the United States with its Australian assets moving to new hands for $55M
Four organisations have been selected to provide comprehensive genomic profiling for 25,000 Australians in the next phase of this screening program
Mega license agreement inked with Chinese powerhouse covering six antibody-drug conjugate and T-cell engager programs